UPDATE - Barclays Downgraded Hospira (HSP) to Equalweight; Expecting a Challenging 2012
Tweet Send to a Friend
UPDATE - Barclays downgraded Hospira (NYSE: HSP) from Overweight to Equalweight, price target slashes from $64 to $44.
Barclays analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
